JPMorgan Chase Reiterates “CHF 84” Price Target for Novartis (NOVN)

JPMorgan Chase set a CHF 84 price objective on Novartis (VTX:NOVN) in a research note released on Monday morning. The firm currently has a neutral rating on the stock.

Several other equities research analysts have also recently commented on the company. Cfra set a CHF 88 price target on Novartis and gave the stock a buy rating in a research note on Friday, April 20th. Credit Suisse Group set a CHF 80 price target on Novartis and gave the stock a sell rating in a research note on Friday, April 20th. Barclays set a CHF 75 price target on Novartis and gave the stock a sell rating in a research note on Friday, April 20th. UBS set a CHF 80 price target on Novartis and gave the stock a neutral rating in a research note on Thursday, April 19th. Finally, Sanford C. Bernstein set a CHF 90 price target on Novartis and gave the stock a buy rating in a research note on Thursday, April 19th. Three investment analysts have rated the stock with a sell rating, seven have issued a hold rating and ten have given a buy rating to the company’s stock. Novartis currently has an average rating of Hold and a consensus target price of CHF 87.85.

Novartis stock opened at CHF 78.38 on Monday. Novartis has a 12 month low of CHF 72.45 and a 12 month high of CHF 88.30.

WARNING: “JPMorgan Chase Reiterates “CHF 84” Price Target for Novartis (NOVN)” was first reported by Ticker Report and is the property of of Ticker Report. If you are accessing this piece on another site, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The original version of this piece can be read at https://www.tickerreport.com/banking-finance/3389672/jpmorgan-chase-reiterates-chf-84-price-target-for-novartis-novn.html.

Novartis Company Profile

Novan, Inc, a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris.

Analyst Recommendations for Novartis (VTX:NOVN)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Financial Survey: Milacron  vs. Amtech Systems
Financial Survey: Milacron vs. Amtech Systems
Synchronoss Technologies  vs. Wipro  Head-To-Head Review
Synchronoss Technologies vs. Wipro Head-To-Head Review
Hecla Mining  and Martin Marietta Materials  Head to Head Analysis
Hecla Mining and Martin Marietta Materials Head to Head Analysis
Citigroup Raises Imperial Oil  Price Target to C$43.00
Citigroup Raises Imperial Oil Price Target to C$43.00
Endeavour Mining  Earns Outperform Rating from Scotiabank
Endeavour Mining Earns Outperform Rating from Scotiabank
Canadian Imperial Bank of Commerce  Given New C$135.00 Price Target at Royal Bank of Canada
Canadian Imperial Bank of Commerce Given New C$135.00 Price Target at Royal Bank of Canada


© 2006-2018 Ticker Report. Google+.